Literature DB >> 29296976

ATG in allogeneic stem cell transplantation: standard of care in 2017? Point.

Andrea Bacigalupo1.   

Abstract

Publisher's Note: This article has a companion Counterpoint by Kekre and Antin. Publisher's Note: Join in the discussion of these articles at Blood Advances Community Conversations.

Year:  2017        PMID： 29296976      PMCID： PMC5728596          DOI： 10.1182/bloodadvances.2016001560

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  22 in total

1.  Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.

Authors:  Andrea Bacigalupo; Teresa Lamparelli; Giovanni Barisione; Paolo Bruzzi; Stefano Guidi; Paolo Emilio Alessandrino; Paolo di Bartolomeo; Rosi Oneto; Barbara Bruno; Nicoletta Sacchi; Maria Teresa van Lint; Alberto Bosi
Journal:  Biol Blood Marrow Transplant       Date:  2006-05       Impact factor: 5.742

2.  Antihuman thymocyte globulin for prophylaxis of graft-versus-host disease. A randomized trial in patients with leukemia treated with HLA-identical sibling marrow grafts.

Authors:  P L Weiden; K Doney; R Storb; E D Thomas
Journal:  Transplantation       Date:  1979-04       Impact factor: 4.939

Review 3.  Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Frédéric Baron; Mohamad Mohty; Didier Blaise; Gérard Socié; Myriam Labopin; Jordi Esteve; Fabio Ciceri; Sebastian Giebel; Norbert Claude Gorin; Bipin N Savani; Christoph Schmid; Arnon Nagler
Journal:  Haematologica       Date:  2016-12-07       Impact factor: 9.941

Review 4.  Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review.

Authors:  A Kumar; A R Mhaskar; T Reljic; R S Mhaskar; M A Kharfan-Dabaja; C Anasetti; M Mohty; B Djulbegovic
Journal:  Leukemia       Date:  2011-12-20       Impact factor: 11.528

5.  Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia.

Authors:  Alois Gratwohl; Ronald Brand; Jane Apperley; Anja v Biezen Av; Giuseppe Bandini; Agnes Devergie; Anton Schattenberg; Francesco Frassoni; Cesare Guglielmi; Simona Iacobelli; Mauricette Michallet; Hans-Jochen Kolb; Tapani Ruutu; Dietger Niederwieser
Journal:  Blood       Date:  2002-12-01       Impact factor: 22.113

6.  Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.

Authors:  Sally Arai; Mukta Arora; Tao Wang; Stephen R Spellman; Wensheng He; Daniel R Couriel; Alvaro Urbano-Ispizua; Corey S Cutler; Andrea A Bacigalupo; Minoo Battiwalla; Mary E Flowers; Mark B Juckett; Stephanie J Lee; Alison W Loren; Thomas R Klumpp; Susan E Prockup; Olle T H Ringdén; Bipin N Savani; Gérard Socié; Kirk R Schultz; Thomas Spitzer; Takanori Teshima; Christopher N Bredeson; David A Jacobsohn; Robert J Hayashi; William R Drobyski; Haydar A Frangoul; Görgün Akpek; Vincent T Ho; Victor A Lewis; Robert Peter Gale; John Koreth; Nelson J Chao; Mahmoud D Aljurf; Brenda W Cooper; Mary J Laughlin; Jack W Hsu; Peiman Hematti; Leo F Verdonck; Melhelm M Solh; Maxim Norkin; Vijay Reddy; Rodrigo Martino; Shahinaz Gadalla; Jenna D Goldberg; Philip L McCarthy; José A Pérez-Simón; Nandita Khera; Ian D Lewis; Yoshiko Atsuta; Richard F Olsson; Wael Saber; Edmund K Waller; Didier Blaise; Joseph A Pidala; Paul J Martin; Prakash Satwani; Martin Bornhäuser; Yoshihiro Inamoto; Daniel J Weisdorf; Mary M Horowitz; Steven Z Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2014-10-30       Impact factor: 5.742

7.  Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.

Authors:  Gérard Socié; Claudia Schmoor; Wolfgang A Bethge; Hellmut D Ottinger; Matthias Stelljes; Axel R Zander; Liisa Volin; Tapani Ruutu; Dominik A Heim; Rainer Schwerdtfeger; Karin Kolbe; Jiri Mayer; Johan A Maertens; Werner Linkesch; Ernst Holler; Vladimir Koza; Martin Bornhäuser; Hermann Einsele; Hans-Jochem Kolb; Hartmut Bertz; Matthias Egger; Olga Grishina; Jürgen Finke
Journal:  Blood       Date:  2011-04-05       Impact factor: 22.113

8.  Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant.

Authors:  Qaiser Bashir; Mark F Munsell; Sergio Giralt; Leandro de Padua Silva; Manish Sharma; Daniel Couriel; Alexandre Chiattone; Uday Popat; Muzaffar H Qazilbash; Marcelo Fernandez-Vina; Richard E Champlin; Marcos J de Lima
Journal:  Leuk Lymphoma       Date:  2011-12-05

9.  Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease.

Authors:  Jeanne Palmer; Xiaoyu Chai; Paul J Martin; Daniel Weisdorf; Yoshihiro Inamoto; Joseph Pidala; Madan Jagasia; Steven Pavletic; Corey Cutler; Georgia Vogelsang; Sally Arai; Mary E D Flowers; Stephanie J Lee
Journal:  Haematologica       Date:  2015-02-24       Impact factor: 9.941

10.  Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.

Authors:  Nicolaus Kröger; Carlos Solano; Christine Wolschke; Giuseppe Bandini; Francesca Patriarca; Massimo Pini; Arnon Nagler; Carmine Selleri; Antonio Risitano; Giuseppe Messina; Wolfgang Bethge; Jaime Pérez de Oteiza; Rafael Duarte; Angelo Michele Carella; Michele Cimminiello; Stefano Guidi; Jürgen Finke; Nicola Mordini; Christelle Ferra; Jorge Sierra; Domenico Russo; Mario Petrini; Giuseppe Milone; Fabio Benedetti; Marion Heinzelmann; Domenico Pastore; Manuel Jurado; Elisabetta Terruzzi; Franco Narni; Andreas Völp; Francis Ayuk; Tapani Ruutu; Francesca Bonifazi
Journal:  N Engl J Med       Date:  2016-01-07       Impact factor: 91.245
View more
  4 in total

1.  Incorporation of posttransplant cyclophosphamide as part of standard immunoprophylaxis for all allogeneic transplants: a retrospective, single institution study.

Authors:  Dennis L Cooper; Jacqueline Manago; Vimal Patel; Dale Schaar; Tracy Krimmel; Mary Kate McGrath; Anne Tyno; Yong Lin; Roger Strair
Journal:  Bone Marrow Transplant       Date:  2020-12-01       Impact factor: 5.483

2.  Not all mismatches are equal: importance of alloreactivity direction.

Authors:  Jacinta Perram; Nada Hamad
Journal:  Haematologica       Date:  2022-04-01       Impact factor: 9.941

3.  Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience.

Authors:  Sara Butera; Marco Cerrano; Lucia Brunello; Chiara Maria Dellacasa; Danilo Giuseppe Faraci; Sara Vassallo; Nicola Mordini; Roberto Sorasio; Francesco Zallio; Alessandro Busca; Benedetto Bruno; Luisa Giaccone
Journal:  Ann Hematol       Date:  2021-05-04       Impact factor: 3.673

Review 4.  Allogeneic Stem Cell Transplantation Platforms With Ex Vivo and In Vivo Immune Manipulations: Count and Adjust.

Authors:  Moniek de Witte; Laura G M Daenen; Lotte van der Wagen; Anna van Rhenen; Reiner Raymakers; Kasper Westinga; Jürgen Kuball
Journal:  Hemasphere       Date:  2021-06-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.